MilliporeSigma has expanded its single use cGMP facility with the addition of the Mobius 2000L single-use bioreactor. With this increase in scale, the company can advance recombinant products from cell line development through to late-stage clinical production.
 
At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage MilliporeSigma's Provantage Services available worldwide to help mitigate the risks traditionally associated with upscaling to commercial production.
 
Provantage is a suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization.
 
"Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production," said Udit Batra, chief executive officer, MilliporeSigma. "Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing - at either an existing facility or one we help them design."